Invitae Corporation NVTA is scheduled to report first-quarter 2020 results on May 5, after market close. Its earnings missed estimates in each of the trailing four quarters, the average miss being ...

Spotlight Top Pick InVitae Corp (NYSE:NVTA) has seen its stock decline and one culprit was a recently published article “How a cancer test maker started by former Twitter, Google execs hopes to change ...

(Reuters) - Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process. To ensure its ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...

BURLINGTON, N.C. - Labcorp (NYSE: LH), a prominent provider of laboratory services, announced today the acquisition of select assets from Invitae (OTC:NVTAQ), a medical genetics company. This ...

nvitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has started to expand its offering of genetic tests for rare diseases and pediatric conditions, providing ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

(OTC: NVTAQ), a leading medical genetics company, today announced the launch of its UnlockTM Behind the Seizure® program, which provides accessible and affordable genetic testing for pediatric ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...

Invitae Corporation NVTA is scheduled to report second-quarter fiscal 2019 results on Aug 6, 2019, after market close. In the first quarter of 2019, the company’s loss per share of 47 cents was wider ...

Out-of-pocket payments are relatively painless in Color’s case because of its test’s $249 price tag. Other genetic disease tests can cost more: Ones from San Francisco-based Invitae Corp. (NYSE: NVTA) ...